Familial medullary thyroid carcinoma: Not a distinct entity? Genotype- phenotype correlation in a large family

American Journal of Medicine

Volumn 101, Issue 6, 1996, Pages 635-641

  Moers, André M J ^a   Landsvater, Rudy M ^b   Schaap, Cees ^c   Jansen Schillhorn Van Veen, Joke M ^b   De Valk, Irene A J ^b   Blijham, Geert H ^b   Höppener, Jo W M ^b   Vroom, Thea M ^b   Ploos Van Amstel, Hans Kristian ^b   Lips, Cornelis J M ^b  

^a Zuyderland Medical Centre   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; FAMILIAL CANCER; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOGENE RET; PARATHYROID DISEASE; PHENOTYPE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; SIPPLE SYNDROME; THYROID MEDULLARY CARCINOMA;

ADRENAL GLAND NEOPLASMS; ADULT; AGED; CARCINOMA, MEDULLARY; CYSTEINE; DNA PROBES; DROSOPHILA PROTEINS; FEMALE; GENOTYPE; GERM-LINE MUTATION; HUMANS; HYPERPARATHYROIDISM; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; PEDIGREE; PHENOTYPE; PHEOCHROMOCYTOMA; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; THYROID NEOPLASMS;

EID: 0030437796     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(96)00330-0     Document Type: Article

References (29)

1. 1. Sipple JH. The association of pheochromocytoma with carcinoma of the thyroid gland. Am J Med. 1961;31:163-166.
2. 2. Gorlin RJ, Sedano HO, Vickers SA, Corvaniko S. Multiple rr ucosal neuromas, pheochromocytoma, and medullary carcinoma of the thyroid: a syndrome. Cancer. 1968;22:293-299.
3. 3. Farndon JR, Leight GS, Dilley WG, et al. Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br J Surg. 1986;73:278-281.
4. 4. Hennessey JF, Gray TK, Cooper CW, Ontjes DA. Stimulation of thyrocalcitonin secretion by pentagastrin and calcium in two patients with medullary thyroid carcinoma. J Clin Endocrin Metab. 1973;36:200-203.
5. 5. Bouillon R, Coopmans W, Degroote DEH, et al. Immunoradiometric assay of parathyrin with polyclonal and monoclonal region specific antibodies. Clin Chem. 1990;36:271-276.
6. 6. Mulligan LM, Kwok JBJ, Healy CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia syndrome type 2A. Nature. 1993;363:458-460.
7. 7. Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet. 1993;2:851-856.
8. 8. Hofstra RMW, Landsvater RM, Ceccherini I, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature. 1994;367:375-376.
9. 9. Landsvater RM, Jansen RPM, Hofstra RMW, et al. Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A, MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A. Hum Genet. 1996;97:11-14.
10. 10. Pachnis V, Mankoo B, Costantini F. Expression of the c-ret proto-oncogene during mouse embryogenesis. Development. 1993;119:1005-1017.
11. 11. Schuchardt A, D'Agati V, Larsson-Blomberg L, et al. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature. 1994;367:380-383.
12. 12. Eng C, Smith DP, Mulligan LM, et al. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene. 1995;10:509-513.
13. 13. Bolino A, Schuffenecker I, Luo Y, et al. RET mutations in exons 13 and 14 of FMTC patients. Oncogene. 1995;10:2415-2419.
14. 14. Santoro M, Carlomagno F, Romano A, et al. Activation of RET as a dominant transforming gene by germline mutations of MEN 2A and MEN 2B. Science. 1995;267:381-383.
15. 15. Asai N, Iwashita T, Matsuyama M, Takahashi M. Mechanism of activation of the RET proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol. 1995;15:1613-1619.
16. 16. Romeo G, Ronchetto P, Luo Y, et al. Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease. Nature. 1994;367:377-378.
17. 17. Edery P, Lyonnet S, Mulligan LM, et al. Mutations of the RET proto-oncogene in Hirschprung's disease. Nature. 1994;367:378-380.
18. 18. Pasini B, Borello MG, Greco A, et al. Loss of function effect of RET mutations causing Hirschsprung's disease. Nature Genet. 1995;10:35-41.
19. 19. Zink A, Blind E, Raue F. Determination of serum calcitonin by immunometric two-site assays in normal subjects and patients with medullary thyroid carcinoma. Eur J Clin Biochem. 1992;30:831-835.
20. 20. Parker NC, Levtzow CB, Wright PW, et al. Uniform chromatographic conditions for quantifying urinary catecholamines, metanephrines, vanillylmandelic acid, 5-hydroxy-indoleacetic acid by liquid chromatography with electrochemical detection. Clin Chem. 1986;32:1473-1476.
21. 21. Lips CJM, Landsvater RM, Höppener JWM, et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. NEJM. 1994;331:828-835.
22. 22. Gagel RF, Jackson CE, Block MA. Age related probability of development of hereditary medullary thyroid carcinoma. J Pediatr. 1982;101:941-946.
23. 23. Mulligan LM, Eng C, Attie T, et al. Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. Hum Mol Genet. 1994;3:2163-2167.
24. 24. Mulligan LM, Eng C, Healey CS, et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nature Genet. 1994;6:70-74.
25. 25. Hofstra RMW, Stelwagen T, Stulp RP, et al. RET mutations in MEN 2 associated diseases. Am J Hum Genet. 1994;55:A60.
26. 26. Mulligan LM, Marsh DJ, Robinson BG, et al. Genotype-phenotype correlation in MEN 2: report of the International RET Mutation Consortium. J Intern Med. 1995;238:343-346.
27. 27. Hofstra RMW. The RET gene and its associated diseases. The Netherlands: University of Groningen; 1995. Thesis.
28. 28. Höppener JWM, Lips CJM. RET receptor tyrosine kinase gene mutations: molecular biological, physiological and clinical aspects. Eur J Clin Invest. 1996;26:613-624.
29. 29. Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: International RET Mutation Consortium analysis. submitted for publication.